CHB


China Biotech Innovation ETF

Reasons to Consider CHB

High Growth Potential

The China biotech market was valued at nearly $40bn in 2021. Forecasts suggest it could surpass $100bn by 2026, highlighting the substantial room for growth.1

Structural Tailwinds

Health care expenditures in China have grown at an annualized rate of 20% since 2003.2 We believe biotech companies are well-positioned to benefit from further growth in this sector.

Targeted Exposure

In contrast to other funds that offer global or broader health care sector exposure, CHB specifically targets the biotech industry in China.

1Research and Markets, Oct 2022
2Council on Foreign Relations, May 2021

Key Information As of 10/02/23

Inception Date 09/22/20
Total Expense Ratio 0.65%
Net Assets $2.04 million
NAV $7.55
Fact Sheet View the document

ETF Summary

The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.

ETF Objective

The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.

Trading Details As of 10/02/23

Ticker CHB
Bloomberg Index Ticker SOLCHB
CUSIP 37954Y251
ISIN US37954Y2515
Primary Exchange Nasdaq
Shares Outstanding 270,000
Number of Holdings 40
30-Day Median Bid-Ask Spread 1.07%

Distributions As of 10/02/23

30-Day SEC Yield 0.72%
Distribution Frequency Semi-Annually

ETF Prices As of 10/02/23

NAV $7.55 Daily Change -$0.03 -0.40%
Market Price $7.55 Daily Change -$0.01 -0.13%

Performance History

As of recent month & quarter-end (09/30/23)
As of recent month & quarter-end (09/30/23)
Fund NAV Market Price Index
1 Year -10.60% -9.45% -9.99%
3 Years -20.73% -21.02% -20.19%
Since Inception -20.20% -20.27% -19.66%
1 Year -10.60% -9.45% -9.99%
3 Years -20.73% -21.02% -20.19%
Since Inception -20.20% -20.27% -19.66%
Year-to-Date -20.49% -19.35% -20.07%
1 Month 4.26% 2.86% 4.28%
3 Months -1.04% -1.56% -0.88%
Since Inception -49.43% -49.56% -48.38%
Year-to-Date -20.49% -19.35% -20.07%
1 Month 4.26% 2.86% 4.28%
3 Months -1.04% -1.56% -0.88%
Since Inception -49.43% -49.56% -48.38%

Performance is shown on a total return basis (i.e., with gross income reinvested, where applicable). Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated.

Top Holdings As of 10/02/23

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
9.28 2269 HK WUXI BIOLOGICS CAYMAN INC BL6B9P1 5.83 32,450 189,126.47
8.14 300122 C2 CHONGQING ZHIF-A BD5CJY8 6.65 24,950 165,982.07
7.81 000661 C2 CHANGCHUN HIGH-A BD5CDB3 19.00 8,377 159,159.51
6.91 1093 HK CSPC PHARMACEUTI 6191997 0.73 192,300 140,924.99
6.63 300142 C2 WALVAX BIOTECHNOLOGY CO-A BD5CG36 3.22 42,000 135,140.34
4.88 600161 C1 BEIJING TIAN-A BP3R9J4 3.50 28,400 99,493.85
4.83 002422 C2 SICHUAN KELUN-A BD5CL08 3.98 24,700 98,415.79
4.81 002252 C2 SHANGHAI RAAS -A BD5CPJ5 0.95 103,100 98,083.78
4.52 002007 C2 HUALAN BIOLOGI-A BD5CL19 3.03 30,400 92,247.76
3.86 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 2.64 29,850 78,697.55
3.67 ZLAB ZAI LAB LTD-ADR BD9GVY0 23.83 3,143 74,897.69
3.57 300601 C2 SHENZHEN KANGT-A BFY8HT2 4.00 18,193 72,787.42
2.44 1530 HK 3SBIO INC BY9D3L9 0.84 59,500 49,757.10
2.29 300676 C2 BGI GENOMICS CO LTD-A BFY8H58 7.13 6,538 46,622.44
2.26 603392 C1 BEIJING WANTAI-A BMXTWX4 6.56 7,021 46,045.64
2.10 688639 C1 ANHUI HUAHENG BI BNHPNZ4 13.96 3,073 42,884.12
2.06 002030 C2 DAAN GENE CO LTD-A BD5CKW3 1.34 31,380 41,906.05
1.70 002038 C2 BEIJING SL -A BD5CJD7 1.69 20,500 34,689.96
1.68 603127 C1 JOINN LABORATO-A BK94819 3.26 10,506 34,205.18
1.58 300255 C2 HEBEI CHANGSHA-A BD5LWT1 1.83 17,600 32,188.30
1.52 000403 C2 PACIFIC SHUANG-A BMQ8TB5 2.90 10,700 30,991.60
1.40 300482 C2 GUANGZHOU WOND-A BFY8GZ1 3.47 8,200 28,491.72
1.36 688739 C1 LIAONING CHENGDA BNHPPJ2 4.72 5,878 27,767.23
1.23 600195 C1 CHINA ANIMAL HUSBANDRY-A BP3RFX0 1.54 16,300 25,154.22
1.03 688185 C1 CANSINO BIOLOGICS INC-A BMD9JD3 10.60 1,981 20,990.73
0.97 300841 C2 CHENGDU KANGHU-A BMXVCN0 9.15 2,150 19,681.04
0.92 6855 HK ASCENTAGE PHARMA BK9PZW2 2.67 7,000 18,678.46
0.79 688278 C1 XIAMEN AMOYTOP B BNHPMR9 5.31 3,049 16,191.15
0.71 9966 HK ALPHAMAB ONCOLOGY BL6WGG4 1.10 13,100 14,383.57
0.67 688319 C1 CHENGDU OLYMVAX BNHPMZ7 2.47 5,567 13,727.36
0.64 603387 C1 GETEIN BIOTECH INC-A BFB4S90 1.53 8,520 13,054.93
0.59 688317 C1 SHANGHAI ZJ BI-A BQ3RXD3 3.15 3,845 12,098.48
0.49 300318 C2 BEIJING BOHUI -A BMQBTF8 0.78 12,700 9,894.82
0.48 688526 C1 WUHAN KEQIAN B-A BQ3RXJ9 2.83 3,460 9,780.38
0.47 301207 C2 HUALAN BIOLOGI-A BLC7YJ2 4.65 2,050 9,527.13
0.46 688105 C1 NANJING VAZYME B BNHNC28 3.94 2,379 9,381.44
0.38 002880 C2 SHENZHEN WEIGU-A BMTCVX0 4.88 1,600 7,805.41
0.32 688221 C1 FRONTIER BIOTECH BNHPM57 1.50 4,399 6,602.15
0.21 1167 HK JACOBIO PHARMACE BMQC6Q1 0.41 10,500 4,289.79
0.18 9939 HK KINTOR PHARMACEUTICAL LTD BMDWVN6 0.35 10,300 3,603.17
0.11 OTHER PAYABLE & RECEIVABLES 1.00 2,237 2,236.87
0.06 CASH 1.00 1,307 1,306.58
0.01 CHINESE YUAN RENMINBI 0.14 767 104.81
0.00 CURRENCY CONTRACT - USD 0.00 105 0.00
0.00 CURRENCY CONTRACT - USD 0.00 -767 -0.01
Holdings are subject to change. "Cash" denotes U.S. dollars.

Exposure As of 09/30/23

Industry Weight (%)
Biotechnology 81.3
Pharmaceuticals: Other 8.7
Pharmaceuticals: Generic 7.4
Medical Specialties 1.5
Pharmaceuticals: Major 1.1

Source: new windowAltaVista Research, LLC

All Sector, Industry and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.

ETF Characteristics As of 10/02/23

Return on Equity 11.20%
Weighted Avg. Market Cap 7,010 M
2022 2023
Price-to-earnings 37.54 26.09
Price-to-book value 3.05 2.80

Source: new windowAltaVista Research, LLC

ETF Risk Stats As of 09/30/23

Versus Beta
S&P 500 0.27
NASDAQ-100 0.23
MSCI EAFE 0.42
MSCI Emg. Mkts 0.78
Standard Deviation 28.50%

Source: new windowAltaVista Research, LLC

ETF Research

View More Related Research

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.